Benefits
Hot flash and night sweat reduction
A 12-week double-blind RCT demonstrated EstroG-100® significantly reduced hot flash frequency and severity, night sweat episodes, and overall vasomotor symptom scores compared to placebo. The effect size was clinically meaningful — comparable to low-dose hormone therapy outcomes — without any estrogenic mechanism.
Sleep quality improvement
EstroG-100® significantly improves sleep quality, reduces nighttime waking, and improves sleep duration in menopausal women. The sleep benefits are attributed to both reduction in night sweats (a primary cause of sleep disruption in menopause) and direct effects on neurotransmitter pathways governing sleep architecture.
Vaginal dryness and urogenital symptom relief
Clinical studies confirm EstroG-100® reduces vaginal dryness, urogenital discomfort, and related quality-of-life impairments in menopausal women. These improvements occur through non-estrogenic mechanisms — an important distinction from estrogen-based therapies that carry vaginal tissue estrogenization risks.
Mood, anxiety, and cognitive symptom improvement
EstroG-100® significantly reduces menopausal mood disturbances including irritability, anxiety, and depression, as well as cognitive symptoms like memory lapses and concentration difficulties. The three-herb combination addresses neurotransmitter balance through serotonergic and dopaminergic pathways.
Safe for estrogen-sensitive conditions
The most clinically important differentiator of EstroG-100®: multiple safety studies confirm it does not stimulate estrogen receptors (ERα or ERβ), does not increase breast cancer cell proliferation (MCF-7 assay negative), and does not increase endometrial thickness. Published clinical data in breast cancer survivors on tamoxifen confirms safety and efficacy without interference with cancer treatment.
Mechanism of action
Non-estrogenic neurotransmitter modulation
EstroG-100® bioactives from the three-herb combination modulate serotonergic (5-HT2A) and dopaminergic (D2) receptors in the hypothalamus — the brain region governing thermoregulation, mood, and sleep. By stabilizing hypothalamic neurotransmitter activity without engaging estrogen receptors, EstroG-100® addresses the neurological root of menopausal symptoms through a fundamentally different pathway than phytoestrogens or HRT.
HPA axis normalization and cortisol modulation
The adaptogenic herb components — particularly Cynanchum wilfordii — normalize hypothalamic-pituitary-adrenal (HPA) axis activity, reducing the cortisol dysregulation that accompanies perimenopause and amplifies hot flashes, sleep disruption, and mood instability. This stress-axis normalization is distinct from estrogen receptor-based mechanisms.
Collagen and mucosal tissue support
Angelica gigas constituents (decursin, decursinol angelate) support collagen synthesis and mucosal tissue integrity through mechanisms independent of estrogen signaling — contributing to improvements in vaginal dryness and skin health observed in clinical trials without the estrogenization risks of topical estrogen therapy.
Clinical trials
Randomized, double-blind, placebo-controlled trial of EstroG-100® (514 mg/day, a standardized blend of Cynanchum wilfordii, Phlomis umbrosa, Angelica gigas) vs placebo in 64 menopausal women for 12 weeks. Outcomes: Menopause Rating Scale (MRS), individual symptom scores. (Phytother Res)
64 menopausal women. 12-week intervention.
EstroG-100® produced significant improvements across MRS subscales — vasomotor (hot flashes, night sweats), psychological (mood, anxiety), and somatic. Industry-funded (Naturalendo Tech). Effects emerge within 4-12 weeks. Note: EstroG-100® is positioned as 'non-phytoestrogenic' — claimed not to bind estrogen receptors despite menopausal benefits — but the mechanistic claims are debated.
Open-label safety study examining EstroG-100® supplementation in breast cancer survivors on tamoxifen therapy for 12 weeks. Outcomes: menopausal symptoms, tamoxifen pharmacokinetics, estradiol, FSH. Note: full peer-reviewed publication may be limited; primary documentation through Naturalendo Tech.
64 pre-, peri-, and postmenopausal women (not cancer survivors — population correction). Randomized, double-blind, placebo-controlled trial for 12 weeks; 514 mg/day EstroG-100® (Cynanchum wilfordii + Phlomis umbrosa + Angelica gigas) vs placebo. White Hispanic, White non-Hispanic, and African American participants.
Kupperman Menopause Index score significantly reduced from 29.5 to 11.3 in EstroG-100® group (p<0.01) vs placebo (29.2 → 23.7). Significant improvements in vaginal dryness scores. No serious adverse events; no significant weight gain. Established efficacy for hot flashes, sweating, sleep disturbances, mood changes, and joint pain. Multiethnic population. Correction: original NutraSmarts entry incorrectly characterized this as a "Breast Cancer Survivors" trial — the actual study population was general menopausal women, no cancer history.
Extended 24-week double-blind clinical trial examining sustained efficacy and safety of EstroG-100® in menopausal women. Outcomes: sustained MRS improvements, sleep quality, quality of life. (Lee et al. 2015 — extension of)
Menopausal women.
Benefits observed at 12 weeks maintained and modestly expanded at 24 weeks. Sleep quality, vasomotor symptoms, and quality of life all improved. Generally well-tolerated. Adds longer-term efficacy data for EstroG-100® specifically.